Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Utility of Xolair in Patients Undergoing Aspirin Desensitization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years.~* Fulfill diagnostic criteria for AERD (described below), and be a candidate for aspirin desensitization chronic asthma - frequently moderate-severe or severe patients will have history compatible with variable airflow obstruction. chronic rhinosinusitis - usually requiring previous sinus surgery procedure(s). sinusitis will have been confirmed by imaging studies presently and/or in the past.~history of adverse reaction to aspirin and/or aspirin-like drugs (e.g., ibuprofen, naproxen, etc.) compatible with AERD.~• Candidate for Xolair \[Omalizumab\] Moderate-severe persistent asthma IgE = 30-700 IU/ml IgE mediated (allergic) potential to inhalant allergen(s) by cutaneous or in vitro testing.~Exclusion Criteria:~* Women of childbearing potential not using appropriate contraception method(s)~* Women currently breastfeeding~* Women who desire to become pregnant during the time of participation in this study~* Men who desire to get someone pregnant during participation in this study~* Known sensitivity to Xolair \[Omalizumab\].~* IgE level \< 30 IU/ml, or \> 700 IU/ml.~* No evidence of atopy by immediate hypersensitivity skin testing~* Use of any other investigational agent in the last 30 days~* Age \< 18 years.~* Current tobacco habituation.~* Presence of emphysema~* Ethanolism or drug abuse within last 12 months.~* Presence of significant medical condition including malignancy, neurologic, kidney, gastrointestinal, liver or cardiovascular disease~* extensive travel commitments during the study that would interfere with study measurements or clinic visits.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo Group (Type: PLACEBO_COMPARATOR): Subjects randomized to placebo
- Omalizumab Group (Type: ACTIVE_COMPARATOR): Subjects randomized to omalizumab

Based on this trial design, predict the completion outcome and termination type (if applicable).